orlistat has been researched along with Hepatitis-C* in 2 studies
2 other study(ies) available for orlistat and Hepatitis-C
Article | Year |
---|---|
Activity-based profiling of the proteasome pathway during hepatitis C virus infection.
Hepatitis C virus (HCV) infection often leads to chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. The stability of the HCV proteins is controlled by ubiquitin-dependent and ubiquitin-independent proteasome pathways. Many viruses modulate proteasome function for their propagation. To examine the interrelationship between HCV and the proteasome pathways we employed a quantitative activity-based protein profiling method. Using this approach we were able to quantify the changes in the activity of several proteasome subunits and found that proteasome activity is drastically reduced by HCV replication. The results imply a link between the direct downregulation of the activity of this pathway and chronic HCV infection. Topics: Cell Line, Tumor; Hepacivirus; Hepatitis C; Hepatitis Viruses; Humans; Isoenzymes; Lactones; Orlistat; Proteasome Endopeptidase Complex; Proteome; Signal Transduction; Viral Proteins; Virus Replication | 2015 |
Lipoprotein lipase mediates hepatitis C virus (HCV) cell entry and inhibits HCV infection.
The host-virus interactions leading to cell infection with hepatitis C virus (HCV) are not fully understood. The tetraspanin CD-81 and human scavenger receptor SR-BI/Cla1 are major receptors mediating virus cell entry. However, HCV in patients' sera is associated with lipoproteins and infectious potential of the virus depends on lipoproteins associated to virus particles. We show here that lipoprotein lipase (LPL), targeting triglyceride-rich lipoproteins (TRL) to the liver, mediates binding and internalization of HCV to different types of cells, acting as a bridge between virus-associated lipoproteins and cell surface heparan sulfate proteoglycans (HSPG). The dimeric structure and catalytic activity of LPL are required for LPL-mediated HCV uptake to cells. Unexpectedly, exogenous LPL significantly inhibits HCVcc infection in vitro. This effect is prevented by anti-LPL antibodies and by tetrahydrolipstatin (THL) a specific inhibitor of LPL enzymatic activity. In addition, we show that antibodies directed to apolipoprotein B (ApoB)-containing lipoproteins efficiently inhibits HCVcc infection. Our findings suggest that LPL mediates HCV cell entry by a mechanism similar to hepatic clearance of TRL from the circulation, promoting a non-productive virus uptake. These data provide new insight into mechanisms of HCV cell entry and suggest that LPL could modulate HCV infectivity in vivo. Topics: Animals; Apolipoproteins B; Cell Line; Cell Line, Tumor; CHO Cells; Cricetinae; Cricetulus; Dimerization; Hepacivirus; Heparan Sulfate Proteoglycans; Hepatitis C; Humans; Lactones; Lipoprotein Lipase; Macrophages; Orlistat; Receptors, Lipoprotein; Virus Internalization | 2007 |